Abstract:Drug-induced liver injury (DILI) encompasses a spectrum of clinical disease ranging from mild biochemical abnormalities to acute liver failure. The majority of adverse liver reactions are idiosyncratic, occurring in most instances 5-90 days after the causative medication was last taken. The diagnosis of DILI is clinical, based on history, probability of the suspect medication as a cause of liver injury and exclusion of other hepatic disease. DILI can be hepatocellular (predominant rise in alanine transaminase), cholestatic (predominant rise in alkaline phosphatase) or mixed liver injury. An elevated bilirubin level more than twice the upper limit of normal in patients with hepatocellular liver injury implies severe DILI, with a mortality of approximately 10% and with an incidence rate of 0.7-1.3 per 100,000. Although acute liver failure is rare, 13-17% of all acute liver failure cases are attributed to idiosyncratic drug reactions. Response to drug withdrawal may be delayed up to 1 year with cholestatic liver injury with occasional subsequent progressive cholestasis known as the vanishing bile duct syndrome. Overall, chronic disease may occur in up to 6% even if the offending drug is withdrawn. Antibiotics and NSAIDs are the most common cause of DILI. Statins rarely cause significant liver injury whereas antiretroviral therapy is associated with hepatotoxicity in 10% of treated patients. Multiple mechanisms of DILI have been implicated, including TNF-alpha-activated apoptosis, inhibition of mitochondrial function and neoantigen formation. Risk factors for DILI include age, sex and genetic polymorphisms of drug-metabolising enzymes such as cytochrome P450. In patients with human immunodeficiency virus, the presence of chronic viral hepatitis increases the risk of antiretroviral therapy hepatotoxicity. Over the next decade, the combination of accurate case ascertainment of DILI via clinical networks and the application of genomics and proteomics will hopefully lead to accurate prediction of risk of DILI, so that pharmacotherapy can be optimised with avoidance of adverse hepatic events.

[Drug-induced bile duct injury: progress and challenges]

Recent Advances on Bile Duct Injury after Transcatheter Arterial Chemoembolization for Hepatic Malignancy

Drug-induced cholestatic liver diseases

Cholangiocyte organoids to study drug-induced injury

Bile Duct Injury in Laparoscopic Cholecystectomy ,analysis of 26 Cases

S4576 Unique Case of Vanishing Bile Duct Syndrome Exacerbated by Noncompliance

[The Clinical Features and Prognosis of Drug-Induced Liver Disease].

Pharmacotherapies for Drug-Induced Liver Injury: A Current Literature Review

Overview of Research on Drug-induced Liver Injury

Idiosyncratic drug-induced liver injury: an update on the 2007 overview

Advances in drug-induced liver injury research: in vitro models, mechanisms, omics and gene modulation techniques

Drug-induced liver injury: a comprehensive review

Current epidemiological study of drug-induced liver injury

Insights gained into the injury mechanism of drug and herb induced liver injury in the hepatic microenvironment

Dissecting the molecular pathophysiology of drug-induced liver injury

Idiosyncratic drug-induced liver injury: an overview

A new prognostic model for drug-induced liver injury especially suitable for Chinese population

Diagnosis, Treatment, and Prevention of Iatrogenic Injury in the Lower Part of Common Bile Duct

Mechanism of Hydrophobic Bile Acid-Induced Hepatocyte Injury and Drug Discovery

Drug-induced liver injury in 2007

Mechanism of drug-induced liver injury and hepatoprotective effects of natural drugs